...
首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation
【24h】

Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation

机译:通过白细胞介素-2和TL1A-IG刺激以体内供体调节性T细胞扩增,改善移植物 - 与宿主疾病,但在造血干细胞移植后保留接枝与白血病

获取原文
获取原文并翻译 | 示例
           

摘要

Regulatory T cells (Tregs) are critical for self-tolerance. Although adoptive transfer of expanded Tregs limits graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT), ex vivo generation of large numbers of functional Tregs remains difficult. Here, we demonstrate that in vivo targeting of the TNF superfamily receptor TNFRSF25 using the TL1A-Ig fusion protein, along with IL-2, resulted in transient but massive Treg expansion in donor mice, which peaked within days and was nontoxic. Tregs increased in multiple compartments, including blood, lymph nodes, spleen, and colon (GVHD target tissue). Tregs did not expand in bone marrow, a critical site for graft-versus-malignancy responses. Adoptive transfer of in vivo-expanded Tregs in the setting of MHC-mismatched or MHC-matched allogeneic HSCT significantly ameliorated GVHD. Critically, transplantation of Treg-expanded donor cells facilitated transplant tolerance without GVHD, with complete sparing of graft-versus-malignancy. This approach may prove valuable as a therapeutic strategy promoting transplantation tolerance. (C) 2017 American Society for Blood and Marrow Transplantation.
机译:调节性T细胞(Tregs)对自我容忍至关重要。尽管膨胀的Tregs的通过转移限制了造血干细胞移植(HSCT)后的移植物与宿主疾病(GVHD),但是难以产生的大量功能性Tregs仍然困难。这里,我们证明,使用TL1A-IG融合蛋白的TNF超家族受体TNFRSF25的体内靶向,以及IL-2导致供体小鼠中的瞬时但巨大的Treg膨胀,其在几天内达到峰值并且是无毒的。 Tregs在多个隔间增加,包括血液,淋巴结,脾和结肠(GVHD靶组织)。 Tregs没有在骨髓中扩张,这是一种接枝与恶性反应的关键部位。在MHC - 不匹配或MHC匹配的同种异体HSCT的设定中采用体内膨胀的Tregs进行了显着改善的GVD。批判性地,Treg扩增的供体细胞的移植促进了没有GVHD的移植耐受性,并完全对移植物与恶性肿瘤进行了备注。这种方法可以证明有价值的促进移植耐受性的治疗策略。 (c)2017年美国血液和骨髓移植协会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号